These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 12356200)

  • 1. The multiple sclerosis functional composite: a new clinical outcome measure for multiple sderosis trials.
    Rudick RA; Cutter G; Reingold S
    Mult Scler; 2002 Oct; 8(5):359-65. PubMed ID: 12356200
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlations between multiple sclerosis functional composite, expanded disability status scale and health-related quality of life during and after treatment of relapses in patients with multiple sclerosis.
    Ozakbas S; Cagiran I; Ormeci B; Idiman E
    J Neurol Sci; 2004 Mar; 218(1-2):3-7. PubMed ID: 14759626
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical significance of the multiple sclerosis functional composite: relationship to patient-reported quality of life.
    Miller DM; Rudick RA; Cutter G; Baier M; Fischer JS
    Arch Neurol; 2000 Sep; 57(9):1319-24. PubMed ID: 10987899
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Multiple Sclerosis Functional Composite Measure (MSFC): an integrated approach to MS clinical outcome assessment. National MS Society Clinical Outcomes Assessment Task Force.
    Fischer JS; Rudick RA; Cutter GR; Reingold SC
    Mult Scler; 1999 Aug; 5(4):244-50. PubMed ID: 10467383
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of the Multiple Sclerosis Functional Composite to predict disability in relapsing MS.
    Rudick RA; Cutter G; Baier M; Fisher E; Dougherty D; Weinstock-Guttman B; Mass MK; Miller D; Simonian NA
    Neurology; 2001 May; 56(10):1324-30. PubMed ID: 11376182
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcome measures for multiple sclerosis clinical trials: relative measurement precision of the Expanded Disability Status Scale and Multiple Sclerosis Functional Composite.
    Hobart J; Kalkers N; Barkhof F; Uitdehaag B; Polman C; Thompson A
    Mult Scler; 2004 Feb; 10(1):41-6. PubMed ID: 14760951
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the Expanded Disability Status Scale and the Multiple Sclerosis Functional Composite as clinical endpoints in multiple sclerosis clinical trials: quantitative meta-analyses.
    Bin Sawad A; Seoane-Vazquez E; Rodriguez-Monguio R; Turkistani F
    Curr Med Res Opin; 2016 Dec; 32(12):1969-1974. PubMed ID: 27603119
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessing disability progression with the Multiple Sclerosis Functional Composite.
    Rudick RA; Polman CH; Cohen JA; Walton MK; Miller AE; Confavreux C; Lublin FD; Hutchinson M; O'Connor PW; Schwid SR; Balcer LJ; Lynn F; Panzara MA; Sandrock AW
    Mult Scler; 2009 Aug; 15(8):984-97. PubMed ID: 19667023
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of a multiple sclerosis functional composite as a clinical trial outcome measure.
    Cutter GR; Baier ML; Rudick RA; Cookfair DL; Fischer JS; Petkau J; Syndulko K; Weinshenker BG; Antel JP; Confavreux C; Ellison GW; Lublin F; Miller AE; Rao SM; Reingold S; Thompson A; Willoughby E
    Brain; 1999 May; 122 ( Pt 5)():871-82. PubMed ID: 10355672
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Long-term application of the multiple sclerosis functional composite test in Debrecen, Hungary].
    Mezei Z; Bereczki D; Csiba L; Csépány T
    Ideggyogy Sz; 2006 Nov; 59(11-12):442-7. PubMed ID: 17203882
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Utilization of the multiple sclerosis functional composite in follow-up: relationship to disease phenotype, disability and treatment strategies.
    Ozakbas S; Ormeci B; Idiman E
    J Neurol Sci; 2005 May; 232(1-2):65-9. PubMed ID: 15850584
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical outcome measures for research in multiple sclerosis.
    Balcer LJ
    J Neuroophthalmol; 2001 Dec; 21(4):296-301. PubMed ID: 11756863
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Application of the Multiple Sclerosis Functional Composite in Debrecen].
    Mezei Z; Bereczki D; Csiba L; Csépány T
    Ideggyogy Sz; 2005 Mar; 58(3-4):113-8. PubMed ID: 15887414
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Functional clinical outcomes in multiple sclerosis: Current status and future prospects.
    Karabudak R; Dahdaleh M; Aljumah M; Alroughani R; Alsharoqi IA; AlTahan AM; Bohlega SA; Daif A; Deleu D; Amous A; Inshasi JS; Rieckmann P; Sahraian MA; Yamout BI
    Mult Scler Relat Disord; 2015 May; 4(3):192-201. PubMed ID: 26008936
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Revisiting the multiple sclerosis functional composite: proceedings from the National Multiple Sclerosis Society (NMSS) Task Force on Clinical Disability Measures.
    Ontaneda D; LaRocca N; Coetzee T; Rudick R;
    Mult Scler; 2012 Aug; 18(8):1074-80. PubMed ID: 22740488
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The multiple sclerosis functional composite: a clinically meaningful measure of disability.
    Polman CH; Rudick RA
    Neurology; 2010 Apr; 74 Suppl 3():S8-15. PubMed ID: 20421572
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Binocular low-contrast letter acuity and the symbol digit modalities test improve the ability of the Multiple Sclerosis Functional Composite to predict disease in pediatric multiple sclerosis.
    Waldman AT; Chahin S; Lavery AM; Liu G; Banwell BL; Liu GT; Balcer LJ
    Mult Scler Relat Disord; 2016 Nov; 10():73-78. PubMed ID: 27919503
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low-contrast letter acuity testing captures visual dysfunction in patients with multiple sclerosis.
    Baier ML; Cutter GR; Rudick RA; Miller D; Cohen JA; Weinstock-Guttman B; Mass M; Balcer LJ
    Neurology; 2005 Mar; 64(6):992-5. PubMed ID: 15781814
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The longitudinal relationship between the patient-reported Multiple Sclerosis Impact Scale and the clinician-assessed Multiple Sclerosis Functional Composite.
    Costelloe L; O'Rourke K; McGuigan C; Walsh C; Tubridy N; Hutchinson M
    Mult Scler; 2008 Mar; 14(2):255-8. PubMed ID: 17942522
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Responsiveness and predictive value of EDSS and MSFC in primary progressive MS.
    Kragt JJ; Thompson AJ; Montalban X; Tintoré M; Río J; Polman CH; Uitdehaag BM
    Neurology; 2008 Mar; 70(13 Pt 2):1084-91. PubMed ID: 18184917
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.